Abstract
Prostate cancer is the second leading cause of cancer death in the United States. Treatment options for confined disease are generally successful in prolonging life but long-term cures (10-15 years) are elusive for the majority of patients. The prognosis for advanced extra-capsular prostate cancer is grim. However, we are now entering the era of gene therapy options for treatment of prostate cancer. The human genome project coupled with genomics and proteomics are providing information that will lead to selection of genes for treatment of prostate cancer. The problem is the science of delivery lags behind knowledge of gene function. Thus, it is important to develop therapies that do not require delivery to 100percent of tumor cells but which nevertheless kills the entire cancer by virtue of the bystander effect or other means. This review covers the use, in gene therapy, of apoptotic inducing molecules such as Fas Ligand, and TRAIL which are believed to induce bystander killing activity and Bax which also may function in a similar way.
Keywords: Fas Ligand, bystander killing activity, surgical castration, immuno histochemistry, apoptosis inducing genes, cis diamminedichloroplatinum, anti apoptotic proteins, chemotherapeutic agents, voltage dependent anion, Bax expression, tetracycline transcriptional
Current Gene Therapy
Title: The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Volume: 1 Issue: 1
Author(s): J. S. Norris, M. L. Hyer, C. Voelkel-Johnson, S. L. Lowe, S. Rubinchik and J-Y. Dong
Affiliation:
Keywords: Fas Ligand, bystander killing activity, surgical castration, immuno histochemistry, apoptosis inducing genes, cis diamminedichloroplatinum, anti apoptotic proteins, chemotherapeutic agents, voltage dependent anion, Bax expression, tetracycline transcriptional
Abstract: Prostate cancer is the second leading cause of cancer death in the United States. Treatment options for confined disease are generally successful in prolonging life but long-term cures (10-15 years) are elusive for the majority of patients. The prognosis for advanced extra-capsular prostate cancer is grim. However, we are now entering the era of gene therapy options for treatment of prostate cancer. The human genome project coupled with genomics and proteomics are providing information that will lead to selection of genes for treatment of prostate cancer. The problem is the science of delivery lags behind knowledge of gene function. Thus, it is important to develop therapies that do not require delivery to 100percent of tumor cells but which nevertheless kills the entire cancer by virtue of the bystander effect or other means. This review covers the use, in gene therapy, of apoptotic inducing molecules such as Fas Ligand, and TRAIL which are believed to induce bystander killing activity and Bax which also may function in a similar way.
Export Options
About this article
Cite this article as:
Norris S. J., Hyer L. M., Voelkel-Johnson C., Lowe L. S., Rubinchik S. and Dong J-Y., The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer, Current Gene Therapy 2001; 1 (1) . https://dx.doi.org/10.2174/1566523013348977
DOI https://dx.doi.org/10.2174/1566523013348977 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Candida Infections and Human Defensins
Protein & Peptide Letters Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Wasp Venom Toxins as a Potential Therapeutic Agent
Protein & Peptide Letters TRAIL: A Potential Agent for Cancer Therapy
Current Molecular Medicine Ghrelin: New Insight to Mechanisms and Treatment of Postoperative Gastric Ileus
Current Pharmaceutical Design Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Inhibition of Molecular Signaling in Huh-7 Cells by AM3: A Novel Chemotherapeutic Agent for Hepatocellular Carcinoma
Medicinal Chemistry The Impact of the Theory-Based Training on Beliefs of Women towards Breast Cancer Screening Behaviors
Current Women`s Health Reviews Active Targeting Strategies for Anticancer Drug Nanocarriers
Current Drug Delivery Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Matrix Metalloproteinases in Cancer Metastasis: Molecular Targets for Prostate Cancer Prevention by Green Tea Polyphenols and Grape Seed Proanthocyanidins
Endocrine, Metabolic & Immune Disorders - Drug Targets The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry New Dehydroepiandrosterone-triazole Derivatives Identified as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Enzyme in the Prostate
Current Enzyme Inhibition Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Glyoxalase Pathway of Trypanosomatid Parasites: A Promising Chemotherapeutic Target
Current Drug Targets The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets